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Abstract
Purpose The patient concerns inventory (PCI) is a prompt list allowing head and neck cancer (HNC) patients to discuss 
issues that otherwise might be overlooked. This trial evaluated the effectiveness of using the PCI at routine outpatient clinics 
for one year after treatment on health-related QOL (HRQOL).
Methods A pragmatic cluster preference randomised control trial with 15 consultants, 8 ‘using’ and 7 ‘not using’ the PCI 
intervention. Patients treated with curative intent (all sites, disease stages, treatments) were eligible.
Results Consultants saw a median (inter-quartile range) 16 (13–26) patients, with 140 PCI and 148 control patients. Of the 
pre-specified outcomes, the 12-month results for the mean University of Washington Quality of Life (UW-QOLv4) social-
emotional subscale score suggested a small clinical effect of intervention of 4.6 units (95% CI 0.2, 9.0), p = 0.04 after full 
adjustment for pre-stated case-mix. Results for UW-QOLv4 overall quality of life being less than good at 12 months (primary 
outcome) also favoured the PCI with a risk ratio of 0.83 (95% CI 0.66, 1.06) and absolute risk 4.8% (− 2.9%, 12.9%) but 
without achieving statistical significance. Other non-a-priori analyses, including all 12 UWQOL domains and at consult-
ant level also suggested better HRQOL with PCI. Consultation times were unaffected and the number of items selected 
decreased over time.
Conclusion This novel trial supports the integration of the PCI approach into routine consultations as a simple low-cost means 
of benefiting HNC patients. It adds to a growing body of evidence supporting the use of patient prompt lists more generally.
Keywords Head and neck cancer · Patient concerns inventory · Quality of life · Patient-reported outcomes · Intervention · 
Randomised trial
Abbreviations
DT  Distress thermometer
EQ-5D-5 L  EuroQol 5 dimension questionnaire
HNC  Head and neck cancer
HRQOL  Health-related quality of life
MDT  Multi-professional team
PCI  Patients concerns inventory
PCI-HN  Patient concerns inventory-head neck
QOL  Quality of life
RCT  Randomised controlled trial
UWQOL  University of Washington QOL 
questionnaire
UWQOLv4  University of Washington QOL question-
naire version 4
Introduction
Health-related quality of life (HRQOL) is a key outcome 
in cancer care. The evaluation of HRQOL is complex 
with many factors involved [1]. For head and neck can-
cer (HNC) survivors, HRQOL is not only influenced by 
site of the tumour, stage and treatment [2] but shaped by 
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patient–clinician relationship, identification of needs, par-
ticipation in therapeutic alliance, and quality of the reha-
bilitation service provision [3]. Following treatment, HNC 
patients have a wide variety and level of unmet needs, with 
psychological unmet needs being most prevalent [4]. Emo-
tional concerns can be difficult to elicit indicating the impor-
tance of undertaking holistic assessments in an attempt to 
uncover unmet needs [5].
The patient concerns inventory (PCI) was first pub-
lished in 2009 [6] and is a condition-specific prompt list 
that allows patients to raise concerns that otherwise might 
be overlooked [7]. A recent systematic review and content 
comparison of unmet needs self-report measures used in 
patients with HNC favoured the PCI compared to 13 other 
tools [8]. The PCI consists of 56 clinical items and has been 
used by patients in outpatient clinics, before seeing their 
consultant. The list guides the outpatient consultation and it 
covers a range of symptoms and potential problems patients 
may face after treatment. It has been shown to be feasible in 
routine consultations [9, 10] and for wider adoption across 
a cancer network [11]. It is possible to augment the PCI 
with feedback from the patient as to their HRQOL outcome 
and one example of this is through the use of the University 
of Washington questionnaire (UW-QOLv4) [12, 13]. The 
combination of the PCI and UW-QOL has been shown to be 
feasible in routine practice and early evidence would suggest 
that their use in consultations could have a beneficial impact 
on quality of life [14, 15]. With established cut-offs, it is 
possible to highlight those doing less well [16]. As outlined 
in the trial protocol [17] and baseline findings [18], the trial 
intervention involved a one-page patient summary sheet that 
was printed following patient completion of the question-
naires on an iPad. This information sheet showed the PCI 
items flagged, domains of UW-QOL dysfunction, overall 
QOL, distress thermometer (DT) score and number of health 
professionals that patients identified as possibly wishing to 
see, were taken into the consultation with the patient.
The PCI has never before been tested in a randomised 
trial. Hence, the main aim of this paper is to report the 
a-priori outcomes of the trial, specifically overall quality 
of life, social–emotional dysfunction and distress follow-
ing repeated use of the PCI based summary sheet after a 
one-year period. Other important outcomes, such as cost-
effectiveness, in terms of quality-adjusted life years (QALY), 
health service use and costs and the cost of the PCI interven-
tion will be reported in a separate paper.
Methods
The methods have been described in full [18]. The study was 
a pragmatic cluster-controlled trial conducted at two UK 
Cancer Centres in Aintree and Leeds, UK. All 15 eligible 
consultants (the clustering factor) were randomised, 8 to 
‘using’ and 7 to ‘not using’ an intervention incorporating 
the PCI prompt list at all their trial clinics. Consultants with 
preferences were given their preferred group and those with-
out preference were randomised, so as to limit the possibility 
of PCI-sceptics dominating the PCI group and PCI-enthu-
siasts the non-PCI group. Preference-based methodologies 
have been used in the evaluation of interventions that are 
about clinical behaviour change to minimise the impact of 
pre-conceived ideas [19]. Allocation was overseen by the 
trial medical statistician, before any patient recruitment and 
was blind to consultant name. In Leeds, three consultants 
preferred to use the PCI, while three without preference 
became controls. In Liverpool, three consultants preferred 
to be controls and the other five without preference were 
randomised, one as a control and four to using the PCI. A 
new Aintree consultant, in post soon after the trial began, 
was randomised to the PCI group. Quality assurance was by 
initial training and booster sessions for PCI consultants and 
through a post-consultation survey of PCI patients asking 
how much the consultant had made reference to the PCI 
prompt sheet during the consultation.
Eligible patients were treated curatively for primary HNC 
and included all sites, stages of disease and treatments. 
Patients treated palliatively or for recurrence, or with his-
tory of cognitive impairment, psychoses or dementia were 
excluded. The first baseline clinic was in April 2017, and to 
aid recruitment to this novel trial, second primary tumours 
were accepted from January 2018. Eligible patients were 
given written information about the trial and willing par-
ticipants were asked to provide written consent when they 
next attended hospital. Patients consented to their clinical 
data being used and to completing research questionnaires 
before each post-treatment consultation, information from 
which could be used in their consultation. Neither consult-
ants nor patients were blind to the randomisation, this being 
a pragmatic trial.
Pre-consultation questionnaires including the PCI prompt 
list were completed electronically apart from one Liverpool 
hospital (non-PCI consultant) that used paper. Patient con-
cerns inventory patients took into their consultations a sum-
mary sheet of paper that listed (a) all PCI items they selected 
for discussion, (b) any University of Washington (UWQOL) 
questionnaire domains in which there was a significant prob-
lem or dysfunction, (c) their overall QOL response (d) their 
DT score and (e) health professionals they wanted to see. 
This one-page paper summary printout was the visible dif-
ference between trial arms as far as contact between consult-
ant and patient was concerned. Control patients completed 
exactly the same pre-clinic information apart from the PCI 
prompt list but neither they nor their consultant saw any 
summary sheet. Both groups completed the EQ-5D-5L for 
purposes of health economic assessment.
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Clinical and demographic data were collected by a base-
line questionnaire or by extraction from electronic records. 
HRQOL data included UW-QOLv4 [12], the DT [20] and 
EQ-5D-5L [21]. The UW-QOL v4 questionnaire consists of 
12 single-item domains, with 3–5 response options scored 
evenly from 0 (worst) to 100 (best) according to response 
hierarchy. UW-QOL domains are presented within two 
subscales, physical function and social–emotional func-
tion [22]. The physical function score is the mean of the 
appearance, swallowing, chewing, speech, taste and saliva 
domain scores, while the social–emotional score is the mean 
of the pain, activity, recreation, shoulder, mood and anxi-
ety domain scores. Criteria derived from earlier work can 
indicate the domains in which patients have a significant 
problem or dysfunction [16]. A single overall QOL question 
on the UWQOL v4 asks patients to consider not only physi-
cal and mental health, but also other factors, such as family, 
friends, spirituality or personal leisure activities important 
to their enjoyment of life; response options are outstanding, 
very good, good, fair, poor, and very poor.
Trial patients were seen in clinic after treatment as per 
normal routine. For analysis, ‘intermediate’ (91–273 days) 
and ‘final’ (≥ 274 days) time windows captured the clin-
ics that fell close to 6 months (183 days) and 12 months 
(365 days) after the baseline trial clinic. For patients seen 
more than once in the intermediate window, the closest 
clinic to 183 days was selected for analysis. In the final 
window, priority selection was given to patients seen after 
12 months and failing this the closest to 365 days. In this 
paper, we will simply refer to results being ‘at 6 months’ 
and ‘at 12 months’.
The pre-specified primary outcome measure was the 
percentage with less than good overall QOL (UWQOLv4) 
at 12 months. Two pre-specified secondary outcomes were 
(A) the percentage with a DT score ≥ 4 and (B) the mean 
social–emotional subscale score of the UWQOLv4. Assum-
ing a control group outcome of 30% for the primary out-
come, an intra-cluster correlation (ICC) value of 0.01, a 
cluster size of 30, and not wishing to miss a halving in out-
come, then 312 patients from ≥ 10 consultants were required 
(with 80% power, 5% level of significance) at 12 months. 
After factoring in 25% attrition/non-consent, 416 were to 
be identified at Multidisciplinary Team (MDT) Meetings. 
For DT ≥ 4, an ICC of 0.01 and a control outcome of 34% 
anticipated, 294 patients were required at 12 months to avoid 
missing a halving in outcome. For the social–emotional 
subscale score, an ICC of 0.025 and a control mean of 75 
anticipated, 221 patients were required at 12 months to avoid 
missing a 10-unit difference in means.
Inference targeted patient outcomes at 12 months. For 
binary outcomes (overall QOL, DT) binary regression 
(STATA v13 binreg procedure) with the rr link option 
estimated treatment-effect risk ratios/differences, P values 
and 95% confidence intervals, with standard errors robust 
to intra-cluster correlation obtained using the option ‘clus-
ter’. Logistic regression (STATA logit) with robust stand-
ard errors and cluster option was also used. Estimates were 
adjusted for baseline values of the outcome, for consultant 
clustering and for pre-specified covariates of gender, age 
(< 55, 55–64, 65–74,  ≥ 75), tumour site (oral cavity, oro-
pharynx, larynx, other), overall clinical grade (early 1–2, 
advanced 3–4), treatment (surgery only, RT or CT/RT only, 
surgery with RT or CT/RT,) and free-flap transfer treatment 
(Yes, No, No surgery). Random effects linear regression 
(STATA xtreg procedure) estimated the treatment-effect dif-
ference in UWQOL socio-emotional mean subscale scores, 
with adjustments for baseline subscale scores (quintile cat-
egories), for consultant clustering and for the pre-specified 
covariates. Standard errors were estimated by a cluster 
bootstrap that resampled with replacement over consultant 
clusters. In non-apriori analyses, the UWQOL physical func-
tion subscale score and all 12 UWQOL domain scores were 
analysed in the same way using random effects linear regres-
sion. Quintile categories were created for baseline physical 
function subscale scores and a three-level categorisation into 
best score (100), dysfunction, and in-between these extremes 
was used for baseline UWQOL domain scores. We used the 
estimator provided by the loneway command in STATA v13 
to estimate outcome ICCs.
The PCI trial had ethical approval from North West-
Liverpool Central Research Ethics Committee REC refer-
ence: IRAS 16/NW/0465, Project ID: 189,554. It also had 
approval from the Health Research Authority (HRA).
The study closed formally on the 30 June 2020 following 
lockdown due to COVID-19 in England on the 24 March 
2020.
Results
Fifteen consultants were eligible and all participated 
throughout the trial seeing a median [Inter-Quartile Range 
(IQR)] of 16 (13–26) patients, range 5–48. Baseline clinics 
ran from April 2017 to October 2019 with 140 interven-
tion PCI and 148 control patients and a total of 1186 trial 
clinic appointments. Median IQR number of clinics for PCI 
patients was 4 (3–5), range 1–10, and for controls 4 (3–6), 
range 1–10. A detailed patient flow chart from MDT to 
baseline clinic has been published [18]. Figure 1 shows the 
flow chart from baseline clinic through to completion of the 
trial. There were final clinic data for 71% of patients in each 
trial group, median IQR 69% (56–82%) for the 15 consult-
ants. Nearly half (46%) of the patient attrition was due to 
cancer recurrence, palliation, 2nd primary and death, with 
5 patients dying (2 PCI, 3 control). One-quarter (27%) of 
the overall loss was due to early closure of the trial because 
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of the COVID-19 pandemic; only 14% was due to patient 
choice/non-compliance. Final trial clinics (referred to as at 
12 months) were a median IQR of 357 (329–380) days after 
baseline for 100 PCI patients and 364 (322–396) days for 
105 controls; intermediate clinics (at 6 months) were 182 
(147–210) days, n = 113 and 175 (147–196) days, n = 126, 
respectively.
Baseline characteristics of PCI and control groups have 
already been described [18]; briefly, the two trial groups 
were similar in demographic and clinical characteristics 
as well as in HRQOL measures apart from differences in 
tumour location, tumour staging and mode of treatment. 
These exceptions were cluster (consultant) related with 
MFU and ENT consultants seeing different types of cases. 
Baseline characteristics of patients with final outcome data 
can be seen in Table 1, and apart from tumour site and mode 
of treatment, the balance between PCI and control groups 
was broadly similar. Overall loss to follow-up was higher in 
patients living alone, not working, in households receiving 
benefits and living in more deprived neighbourhoods. It was 
also higher in those with worse HRQOL and in those hav-
ing free-flap transfer surgery followed by adjuvant therapy.
The median IQR number of PCI items was 5 (2–9) at 
baseline, reducing to 3 (1–7) at 6 months and 2 (0–4) at 
12 months. Dry mouth was the most frequent item selected, 
49% at baseline, 29% at 6 months and 25% at 12 months 
(Fig. 2). Other items most selected throughout the trial were 
fear of the cancer coming back, chewing/eating, salivation, 
fatigue/tiredness and pain in the head/neck. The percentage 
of patients selecting one or more health professionals they 
wanted to see was 46% (65/140) at baseline, 31% (35/113) 
at 6 months and 18% (18/100) at 12 months. Profession-
als most selected at baseline were dentist (16%, 22), sur-
geon (14%, 19), radiotherapist/oncologist (9%, 12), Speech 
& Language therapist (8%, 11) and dental hygienist (8%, 
11). In the post-consultation questionnaire, the vast major-
ity of PCI patients said that their consultant had made ‘a 
great deal’ of reference to the PCI prompt sheet during 
the consultation, 88% (117/133) at baseline, 90% (97/108) 
at 6 months and 93% (91/98) at 12 months. In most other 
instances (13/133, 7/108, 5/98), consultants had ‘somewhat’ 
referenced the prompt sheet, and rarely had they made ‘a 
little’ (3, 3, 1) reference or ‘not at all’ (0, 1, 1). Median IQR 
consultation times at baseline were 11 (8–15) minutes for 
138 PCI and 10 (7–13) minutes for 148 control patients; 
at 6 months: 10 (7–12) minutes for 112 PCI and 10 (7–11) 
minutes for 126 controls; at 12 months: 8 (7–11) minutes for 
97 PCI and 9 (6–12) minutes for 103 controls.
Results for the primary outcome measure, i.e. the per-
centage of patients at 12 months with overall QOL that 
was less than good, favoured the PCI intervention though 
these results were not statistically significant (Table 2). In 
the PCI group, the percentage fell from 30% at baseline to 
22% at 12 months whilst in the control group, it fell from 27 
to 25%. After adjustment for baseline outcome, consultant 
clustering, tumour site and treatment (including free-flap 
transfer), the estimate of risk ratio at 12 months was 0.83 
(95% CI 0.66, 1.06), p = 0.14. Similar adjustments regarding 
absolute risk difference gave an estimate of 4.8% in favour 
of PCI over control with 95% confidence interval ranging 
from 2.9% against PCI to 12.9% for PCI. Results for the 
percentage of patients at 12 months with a DT score ≥ 4 
did not favour either group after adjustment (Table 3); in 
the PCI group, the percentage fell from 45% at baseline to 
33% at 12 months whilst in the control group, it fell from 
36% to 30%. However, it was not possible to further adjust 
either binary measure for age, gender or overall clinical stage 
because of convergence issues. Estimation of odds ratios 
Fig. 1  Patient flow from trial 
baseline to final clinic
PCI paents lost to trial (n=40) 
• Recurrence/palliaon/2nd Primary/death (n=18) 
• Covid (n=11) 
• Paent choice/non-compliance (n=5) 
• Site change (n=3) 
• New disease (n=2) 
• Other (n=1) 
Control  paents lost to trial (n=43) 
• Recurrence/palliaon/2nd Primary/death (n=20) 
• Covid (n=11) 
• Paent choice/non-compliance (n=7) 
• Site change (n=3) 
• Psychosis (n=1) 
• Other  (n=1) 
PCI paents with baseline data  (n=140) Control paents with baseline data  (n=148)
Control paents with final data  (n=105)PCI paents with final data  (n=100)
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Table 1  Baseline characteristics 






Overall loss to 
follow-up
p  value*
PCI Control PCI Control %
All patients 100 105 40 43 29
Site
 Aintree 55 64 27 32 33 0.05
 Leeds 45 41 13 11 22
 Gender
 Female 35 27 14 14 31 0.58
 Male 65 78 26 29 28
Age at baseline clinic
  < 55 20 29 9 13 31 0.68
 55–64 45 42 17 12 25
 65–74 23 23 9 12 31
  ≥ 75 12 11 5 6 32
Tumour site
 Oral cavity 38 53 17 26 32 0.08
 Oropharynx 33 37 9 12 23
 Larynx 17 8 13 3 39
 Other 12 7 1 2 14
Overall stage
 Early 0–2 40 49 16 19 28 0.90
 Advanced 3–4 60 56 24 24 29
Primary  treatment**
 S only 36 37 10 12 23 0.06
 S only & FF 5 12 2 2 19
 RT or RT/CT only 26 13 12 7 33
 S & (RT or RT/CT) 24 27 7 10 25
 S & (RT or RT/CT) & FF 9 16 9 12 46
WHO comorbidity
 0 65 63 23 28 28 0.28
 1 23 28 5 11 24
 2–4 12 14 12 4 38
ACE27 comorbidity
 None 58 49 13 17 22 0.08
 Mild 26 35 15 19 36
 Moderate/severe 16 21 12 7 33
Living situation in house/flat
 Alone 18 21 11 15 40 0.03
 With others 82 83 29 26 25
Working
 Yes 41 31 7 9 18 0.01
 No 55 73 31 33 33
Financial benefits (household)
 Yes 30 38 19 20 36 0.007
 No 64 61 14 19 21
Smoking habit
 Current 12 12 4 9 35 0.60
 Former 60 57 21 25 28
 Never 26 33 12 9 26
Alcohol habit
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gave a similar progression in regard to the primary outcome 
(0.86, 0.77, 0.75 with 0.78 after further adjustment for age, 
gender and stage) and for the DT (1.12, 1.00, 1.18 and then 
0.99). Results for the other a-priori outcome, the UWQOL 
social–emotional subscale mean score at 12 months, also 
favoured the PCI intervention and these results were statisti-
cally significant (Table 4), with the best estimate suggesting 
a small clinical effect of 4.6 units (95% CI 0.2, 9.0), p = 0.04 
after full adjustment.
Since the subscale score is the average of six domain 
scores, a set of extra analyses were done for each domain 
(Table 5), and all of these analyses favoured the PCI inter-
vention, with a mix of small effects suggested for each 
domain. Similar analyses of the UWQOL physical function 
subscale mean score at 12 months, and its six component 
domains, also favoured the PCI intervention with small 
effects observed throughout. The full response range for the 
overall QOL (Table 6) indicated a tendency within each level 
of QOL at baseline for the PCI group to have a better set of 
QOL responses at 12 months; overall QOL improved for 
42% (42) of PCI patients and 30% (31) of control patients. 
Table 7 provides a more simplistic cluster-level descriptive 
summary of the trial data. Six of the 8 PCI consultants saw 
a reduction in the number of their patients having less than 
good overall QOL, in contrast to 3 of the 7 control consult-
ants. The changes in mean socio-emotional subscale scores 
tended to be larger in patients under PCI consultants (median 
7.5) than control consultants (median 3).
Discussion
Interventions aimed at improving the quality of life (QoL) 
of HNC survivors are of critical importance when consider-
ing the increasing number of survivors and the significant 
life-long treatment burden for some patients who have poor 
functional, emotional and social outcomes. It is essential 
to provide robust evidence from randomised trials about 
the effectiveness of psychologically-based interventions 
intended to improve QoL and its subscales. Thus far, such 
intervention studies in HNC patients have produced insuffi-
cient data to support their effectiveness for improving quality 
of life [23–27]. However, there is evidence of benefit in other 
cancers, for example, a randomised trail reporting symptom 
monitoring with patient-reported outcomes during routine 
cancer treatment [28]. In addition, van der Meulen [29] 




Overall loss to 
follow-up
p  value*
PCI Control PCI Control %
 Current 80 66 20 28 25 0.08
 Former 15 30 15 13 38
 Never 4 6 1 2 23
IMD 2019 quintile
 1 = least deprived 12 14 4 4 24 0.01
 2 23 22 6 4 18
 3 18 22 4 5 18
 4 12 10 5 13 45
 5 = most deprived 35 37 21 17 35
UWQOL Overall Quality of life
 Good, V good, Outstanding 70 77 25 27 26 0.16
 Fair, Poor, V poor 30 28 15 16 35
Distress thermometer (DT) score
 0–3 55 67 19 18 23 0.03
 4–10 45 38 21 25 36
UWQOL social-emotional subscale 
score (quintiles)
  < 55.8 10 19 10 18 49 0.002
 55.9–70.0 21 22 9 10 31
 70.1–81.7 25 20 7 3 18
 81.8–90.8 18 16 8 5 28
 90.9–100 26 28 6 7 19
S Surgery, RT Radiotherapy,CT Chemotherapy, FF Free flap transfer
*Fishers exact test
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Fig. 2  PCI items selected at baseline, intermediate and final clinics
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reported that nurse-led psychosocial intervention between 12 
and 24 months after HNC treatment did make a significant 
improvement in emotional and physical functioning, pain, 
swallowing, social contact, mouth opening and depressive 
symptoms.
The outpatient consultation provides an ideal opportu-
nity for integration of a prompt list intervention. The PCI 
can be routinely integrated into clinical care [9, 10], and 
a holistic patient-centred approach seems appropriate any-
way regardless of any significant findings. Furthermore, it is 
something much appreciated and widely accepted by most 
patients [11]. Its use adds an element of quality assurance 
particularly when the patient is less familiar to the consult-
ant or is being reviewed by a more junior member of staff. 
The consultants’ training focused on ensuring that issues 
identified by the patient were considered and if there were 
too many issues raised, there was then an agreement with 
the patient to focus on three or four they felt most impor-
tant. The post-consultation questionnaire confirmed that the 
patients felt the PCI had been used throughout the trial.
The purpose of this paper was to focus on a number of 
outcomes that were specified in advance and for which sam-
ple size calculations were made. Variables used to adjust 
the analyses were also specified in advance, and included 
tumour site, stage and treatment. Therefore, the main con-
fidence interval estimations can be interpreted without 
concern about post hoc selection. Other analyses should be 
regarded as exploratory. Our findings should have gener-
alisability given that all eligible consultants from the two 
hospitals participated throughout the trial. In addition, there 
was good recruitment and sustainability throughout the trial 
in those patients often hard to reach, such as the elderly 
and those in more socially deprived groups. The choice 
of a cluster design is a strength of the study, the rationale 
Table 2  Pre-specified primary outcome: less than good overall QOL at 12 months
a ICC Intra-class correlation estimated as Zero, with 95% confidence interval (0, 0.058)
Baseline 6 months 12 months Risk ratio at 12 months,
with 95% confidence interval and p value
Unadjusted Adjusted for baseline QOL 
& consultant  clusteringa
Adjusted also for tumour 
site, treatment & free-flap
% n % n % n
Data at baseline and in 12 month window





p = 0.14 Control 27 28/105 25 26/105
All available data
 PCI 32 45/140 24 27/113 22 22/100
 Control 30 44/148 24 30/126 25 26/105
Data at baseline and in both 6 and 12 month windows
 PCI 29 26/90 21 19/90 22 20/90
 Control 26 26/101 19 19/101 24 24/101
Table 3  Pre-specified secondary outcome: distress thermometer (DT) score ≥ 4 at 12 months
a ICC Intra-class correlation estimated as 0.00345, with 95% confidence interval (0, 0.064)
Baseline 6 months 12 months Risk ratio at 12 months, with 95% confidence interval and p value
Unadjusted Adjusted for baseline DT 
& consultant  clusteringa
Adjusted also for tumour 
site, treatment & free-flap
% n % n % n
Data at baseline and in 12 month window:





p = 0.85 Control 36 38/105 30 32/105
All available data
 PCI 47 66/140 41 46/113 33 33/100
 Control 43 63/148 37 47/126 30 32/105
Data at Baseline and in both 6 and 12 month windows:
 PCI 46 41/90 38 34/90 34 31/90
 Control 36 36/101 37 37/101 29 29/101
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behind which was discussed in detail in the baseline results 
paper [18]; individual patient randomisation was ruled out 
because of the likely sensitization of consultants to using 
the PCI, which could have led to certain strategies being 
carried over to when control group patients were being seen. 
A further strength of the trial was the relatively small pro-
portion of refusals and withdrawals through patient choice, 
and the number missed for logistical reasons by trial staff 
was also small. Another strength was the electronic data 
capture which, apart from the paper-based baseline ques-
tionnaire, virtually eliminated missing data in the outpatient 
clinic setting.
From this study, in terms of the primary outcome of less 
than good overall QOL at 12 months, the best estimate after 
various adjustments, including baseline level, was an abso-
lute benefit at 12 months of about 5% from the PCI inter-
vention and a risk ratio of 0.83 which suggests about one in 
six patients might benefit. Interpretation, however, is made 
difficult due to wide confidence intervals that include no 
benefit at all.
Perhaps where the PCI approach is helping most for 
patients is through the social–emotional aspect of cancer 
recovery [30]. Although the benefit from PCI interven-
tion of 4.6 units in the social–emotional subscale score 
at 12 months after adjustment seems small, it is clinically 
meaningful [22]. It is of note also that results for all 12 
UW-QOL domains favoured the PCI with a small benefit 
(Table 5), with improvements also seen for both groups over 
time which probably reflects adaption over the year. Fear 
of recurrence is frequently raised by patients on the PCI 
(Fig. 2) and is recognised as a major concern over many 
follow-up consultations [31]. It remains to be fully evalu-
ated but the hypothesis is that the prompt allows the patient 
permission to talk about this aspect and seek reassurance or 
further information. The PCI approach might be very help-
ful for those HNC patients likely to take a more passive role 
in medical consultations, such as patients of lower socio-
economic strata [32].
Previous studies [22] have shown that the domain and 
subscale scores of the UW-QOL, notably the social–emo-
tional subscale, correlate with overall QoL. It is possible that 
the simplicity of the binary primary overall QOL outcome in 
this trial diluted the benefit patients gained from this inter-
vention. When analysing the change in overall QOL across 
all six-response options for overall QOL, the PCI group 
appeared to do slightly better (Table 6). Given the variation 
in numbers of patients by consultant and variation in types 
of patients seen and treated, it was reassuring to see that the 
analyses at consultant level (Table 7) provided some sup-
port, be it at a rather simplistic summary level, of the main 
Table 5  Other UWQOL outcomes (not pre-specified) for 100 PCI and 105 control patients with data at baseline and at 12 months
ICC Intra-class correlation for physical subscale score estimated as 0.0125, with 95% confidence interval of (0, 0.0786)
a Baseline value: Quintile categorisation for UWQOL Physical function; 3-level categorisation into best score, dysfunction, and in-between these 
extremes for the 12 UWQOL domains
Mean (SD) Difference between group means at 12 months,
with 95% confidence interval and p value
Baseline 12 months Unadjusted Adjusted for baseline  
valuea and consultant 
clustering
Adjusted also for tumour site, 
treatment, free-flap, clinical 
stage, age and genderPCI Control PCI Control
UWQOL social–emotional subscale domain scores
 Pain 73 (26) 71 (29) 88 (20) 80 (27) 7.5 (1.1, 13.9) 7.3 (2.0, 12.6) 7.5 (1.9, 13.2)
 Activity 74 (23) 70 (24) 82 (21) 76 (24) 6.3 (0.1, 12.5) 5.0 (0.8, 9.3) 6.8 (0.8, 12.8)
 Recreation 83 (22) 75 (23) 86 (19) 79 (22) 6.5 (0.9, 12.0) 3.8 (− 0.9, 8.5) 3.1 (− 2.4, 8.6)
 Shoulder 82 (26) 73 (33) 87 (25) 81 (28) 5.3 (− 2.1, 12.6) 2.8 (− 2.4, 8.0) 4.7 (− 0.8, 10.1)
 Mood 77 (23) 74 (27) 83 (22) 77 (24) 6.1 (− 0.2, 12.4) 5.2 (1.7, 8.6) 4.2 (− 0.7, 9.1)




71 (17) 69 (20) 81 (15) 76 (20) 5.7 (0.7, 10.6) 4.4 (1.5, 7.3) 4.5 (0.6, 8.4)
UWQOL physical function subscale domain scores
 Appearance 80 (17) 73 (20) 89 (14) 83 (19) 5.2 (0.6, 9.7) 3.2 (− 0.3, 6.6) 2.2 (− 1.4, 5.8)
 Swallowing 78 (22) 76 (23) 86 (16) 80 (25) 5.7 (0.0, 11.4) 4.6 (− 0.1, 9.2) 5.6 (− 0.5, 11.7)
 Chewing 65 (31) 67 (32) 80 (27) 75 (32) 4.7 (− 3.3, 12.8) 5.7 (− 1.3, 12.7) 6.2 (− 3.5, 15.9)
 Speech 83 (18) 79 (21) 90 (15) 83 (20) 6.9 (2.1, 11.7) 4.9 (0.7, 9.2) 4.3 (0.7, 8.0)
 Taste 64 (32) 61 (35) 77 (28) 70 (32) 6.9 (− 1.3, 15.1) 6.8 (0.6, 12.9) 6.7 (− 0.4, 13.7)
 Saliva 58 (32) 57 (33) 67 (32) 62 (31) 4.5 (− 4.1, 13.1) 3.9 (− 2.0, 9.9) 2.3 (− 5.2, 9.8)
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findings reported at patient level. Whereas the unadjusted 
results for the DT (Table 3) tended to favour the PCI, as did 
the results after adjustment for baseline value and clustering, 
the results after full adjustment did not favour either group. 
No trial of this size stands alone as evidence and further 
trials would provide reassurance of the positive indications 
suggested by this trial.
The inclusion of the PCI does not significantly lengthen 
the consultation time since in comparison to the control 
group the first trial PCI consultations only took one minute 
longer on average whilst at 12 months they were one minute 
shorter.
One limitation of the trial was that it was under-pow-
ered, in part from a greater loss of patients than expected 
after identifying likely patients at the MDT and before the 
baseline trial clinic; half of this loss comprised patients 
who could not possibly have started the trial, for exam-
ple, because of death, recurrence, palliation, changes 
in travel to non-trial sites and for other reasons, such as 
being in another trial and having mental health issues 
[18]. Further losses between baseline and the final trial 
clinic (Fig. 1) were predominantly for clinical reasons or 
because of COVID-19. Pragmatically, we accept that “size 
and power are irrelevant once the experiment has actu-
ally been carried out. At this point, the trial is analysed 
using confidence intervals to show the plausible values 
for the treatment effects” [33]. One unavoidable limitation 
was the lack of blinding but this is a distinctive feature of 
pragmatic cluster trials. Since recruitment of patients took 
place after the randomisation of clusters, there was always 
a possibility of selection bias, but this was minimised 
because patients were allocated to individual consultants 
through the cancer tracking referral process without know-
ing which consultants used PCI and which did not.
The focus of the project is now related to wider imple-
mentation of the PCI approach in clinical care, research 
around the mechanisms of action, ways of improving effi-
cacy, and education resources for patients and clinicians. An 
implementation phase could include aspects of patient–clini-
cian communication and patient empowerment. It would be 
interesting to apply the intervention earlier in the follow-up 
of patients as perhaps there might be more benefit, possibly 
starting in the pre-treatment phase. To achieve this, appro-
priate IT infrastructure is required to allow patients to access 
the PCI tool prior to their consultation and allow this to 
be integrated into clinical care. This needs to be part of an 
integrated strategy of engaging patients using IT technology. 
The need for IT solutions around COVID-19 might hasten 
the breakdown of barriers previously encountered by both 
patients and clinicians in respect of IT.
Conclusion
In summary, study is the first randomised controlled trial to 
evaluate the benefit of the PCI approach. Notable strengths 
of this study were the originality (landmark trial) with 15 
consultants in a routine NHS outpatient setting, its clinical 
significance as a low-cost intervention and a strong contribu-
tion made by patients themselves to the design and delivery 
of the trial. Clinicians find the PCI straightforward to use, 
with minimal training, with the vast majority of patients 
appreciating the approach and wishing to continue to use 
it in the future. The study suggests a small but meaningful 
benefit in outcomes from this PCI approach using routine 
care. Such interventions are increasingly important given 
the rising incidence of HNC, more people living longer with 
the burden of treatment-related issues and the importance of 
addressing unmet needs in the early post-treatment survivor-
ship phase.
Table 6  Change in overall QOL from baseline to 12 months
a The UWQOL Overall QOL question has 6 category responses: Out-







 + 4 V poor V good 1 –
 + 1 V poor Poor 2 –
0 V poor V poor 1 2
 + 3 Poor V good 2 –
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